Clinical trial

Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer

NCT01180335

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Chemotherapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Genomic driven chemotherapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-01-01

PhasePHASE3

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

ChemotherapyDRUG

Genomic driven chemotherapyDRUG

Sponsors & collaborators

Gustave Roussy, Cancer Campus, Grand Parislead sponsor

Institut Curiecollaborator

Mapped research locations

VillejuifFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01180335 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.